Investigational Drug Information for PF-07321332
✉ Email this page to a colleague
What is the drug development status for PF-07321332?
PF-07321332 is an investigational drug.
There have been 21 clinical trials for PF-07321332.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 9th 2021.
The most common disease conditions in clinical trials are COVID-19, Renal Insufficiency, and Liver Diseases. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There is one US patent protecting this investigational drug and forty-four international patents.
Summary for PF-07321332
| US Patents | 1 |
| International Patents | 44 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-09-09) |
| Vendors | 27 |
Recent Clinical Trials for PF-07321332
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin | Pfizer | Phase 1 |
| Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. | Pfizer | Phase 1 |
| A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease | Pfizer | Phase 1 |
Clinical Trial Summary for PF-07321332
Top disease conditions for PF-07321332
Top clinical trial sponsors for PF-07321332
International Patents for PF-07321332
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-07321332 | Argentina | AR123111 | 2040-09-03 | ⤷ Sign Up |
| PF-07321332 | Australia | AU2021266232 | 2040-09-03 | ⤷ Sign Up |
| PF-07321332 | Australia | AU2022202158 | 2040-09-03 | ⤷ Sign Up |
| PF-07321332 | Australia | AU2022221493 | 2040-09-03 | ⤷ Sign Up |
| PF-07321332 | Brazil | BR112021022419 | 2040-09-03 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
